Upregulation of six genes (ABCA7, ApoE, CASS4, CELF1, PTK2B, and ZCWPW1) and downregulation of one gene (DSG2) were noted and indicate that PPARγ agonists may represent an attractive class of drugs for preventing or delaying the onset of late onset AD [73]. The gene discussed is APOE; the disease is Alzheimer disease.